NDA@SZTAKI

Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer

Döme, Balázs

Tímár, József

Dobos, Judit

Rásó-Barnett, Lívia

Rásó, Erzsébet

Paku, Sándor

Kenessey, István

Ostoros, Gyula

Ladányi, Andrea

Bogos, Krisztina

Tóvári, József

American Association for Cancer Research

2006

RC0254 Neoplasms. Tumors. Oncology (including Cancer) / daganatok, tumorok, onkolĂłgia

Until recently, it was generally accepted that vascularization
of tumors arises exclusively from endothelial sprouting. Whether
circulating bone marrow-derived endothelial progenitor cells
(EPC) participate in the progression of non-small cell lung
cancer (NSCLC) has not yet been evaluated. EPCs labeled with
CD34, CD133, and vascular endothelial growth factor receptor-2
(VEGFR2) antibodies were counted by flow cytometry in the
peripheral blood of 53 NSCLC patients. Furthermore, by means of
a quantitative reverse transcription-PCR approach, we measured
VEGFR2, CD133, CD34, and VE-cadherin mRNA in the peripheral
blood samples of the same patient population. EPCs in tumor
samples were identified by confocal microscopy using CD31, CD34.
CD133, and VEGFR2 antibodies. Although immunofluorescent
labeling of microvessels made clear that incorporation of EPCs
is a rare phenomenon in NSCLC tissue (9 of 22 cases),
circulating EPC levels before therapeutic intervention were
increased in NSCLC patients (P < 0.002, versus healthy
controls), and high pretreatment circulating EPC numbers
correlated with poor overall survival (P < 0.001). Furthermore,
in the subgroup of responders to treatment, the posttreatment
EPC numbers in the peripheral blood were significantly lower
compared with nonresponding patients. Interestingly,
pretreatment mRNA levels of CD133, VE-cadherin, and CD34 were
not significantly increased in NSCLC patients, whereas VEGFR2
expression was increased by 80-fold. Moreover, posttreatment
VEGFR2 mRNA level in the peripheral blood was significantly
higher in the subgroup of nonresponding patients when compared
with posttreatment level of patients responding to antitumor
therapy. Circulating levels of bone marrow-derived EPCs are
significantly increased in NSCLC patients and correlate with
clinical behavior.

angol

Article

PeerReviewed

info:eu-repo/semantics/article

text

http://real.mtak.hu/44143/1/Dome_CancerRes_u.pdf

Döme, Balázs and Tímár, József and Dobos, Judit and Rásó-Barnett, Lívia and Rásó, Erzsébet and Paku, Sándor and Kenessey, István and Ostoros, Gyula and Ladányi, Andrea and Bogos, Krisztina and Tóvári, József (2006) Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. CANCER RESEARCH, 66 (14). pp. 7341-7347. ISSN 0008-5472

http://real.mtak.hu/44143/

http://dx.doi.org/10.1158/0008-5472.CAN-05-4654

MTMT:1072475; doi:10.1158/0008-5472.CAN-05-4654